Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Aug 19, 2024; 14(8): 1254-1266
Published online Aug 19, 2024. doi: 10.5498/wjp.v14.i8.1254
Published online Aug 19, 2024. doi: 10.5498/wjp.v14.i8.1254
Botulinum toxin type A-targeted SPP1 contributes to neuropathic pain by the activation of microglia pyroptosis
Li-Ping Chen, Fu-Hai Ji, Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
Xiao-Die Gui, Wen-Di Tian, Jin-Zhao Huang, Department of Pain, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
Hou-Ming Kan, Faculty of Medicine, Macao University of Science and Technology, Macau 999078, China
Author contributions: Chen LP and Ji FH designed the research study; Chen LP, Gui XD, and Tian WD performed the research; Chen LP, Kan HM, and Huang JZ analyzed the data; Chen LP and Ji FH wrote the manuscript. All authors have read and approved the final manuscript.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Xuzhou Medical University (No. SC225179).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Hai Ji, MD, Professor, Department of Anesthesiology, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215006, Jiangsu Province, China. jifuhai@suda.edu.cn
Received: April 3, 2024
Revised: May 29, 2024
Accepted: July 2, 2024
Published online: August 19, 2024
Processing time: 130 Days and 18.4 Hours
Revised: May 29, 2024
Accepted: July 2, 2024
Published online: August 19, 2024
Processing time: 130 Days and 18.4 Hours
Core Tip
Core Tip: Neuropathic pain (NP) arises from structural lesions that induce functional abnormalities in the central and peripheral nervous systems. This condition plagues approximately 10% of the population. In this study, we found that microglial pyroptosis was closely correlated with NP progression and that botulinum toxin type A (BTX-A) treatment notably alleviated this. Our mechanistic study identified that SPP1 may be positively correlated with microglial pyroptosis and inflammation during NP and that it is targeted by BTX-A. These findings provide novel evidence for the application of BTX-A in the treatment of NP.